Debt to Equity Ratio Chart

View Debt to Equity Ratio for TGTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.249
March 31, 2026 1.292
December 31, 2025 0.3915
September 30, 2025 0.4178
June 30, 2025 0.9178
March 31, 2025 1.069
December 31, 2024 1.141
September 30, 2024 1.321
June 30, 2024 0.6338
March 31, 2024 0.6975
December 31, 2023 0.6903
September 30, 2023 0.667
June 30, 2023 2.695
March 31, 2023 3.942
December 31, 2022 1.418
September 30, 2022 0.8184
June 30, 2022 0.6231
March 31, 2022 0.464
December 31, 2021 0.3333
September 30, 2021 0.0882
June 30, 2021 0.0909
March 31, 2021 0.0943
December 31, 2020 0.0826
September 30, 2020 0.2435
June 30, 2020 0.213
Date Value
March 31, 2020 -30.40
December 31, 2019 1.062
September 30, 2019 -1.535
June 30, 2019 2.878
March 31, 2019 1.966
December 31, 2018 0.0028
September 30, 2018 0.0013
June 30, 2018 0.0021
March 31, 2018 0.0026
December 31, 2017 0.0019
September 30, 2017 0.0023
June 30, 2017 0.002
March 31, 2017 0.0017
December 31, 2016 0.0019
September 30, 2016 0.0021
June 30, 2016 0.0012
March 31, 2016 0.0017
December 31, 2015 0.0021
September 30, 2015 0.0016
June 30, 2015 0.0026
March 31, 2015 0.0026
December 31, 2014 0.0034
September 30, 2014 0.0027
June 30, 2014 0.0031
March 31, 2014 0.0021

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Krystal Biotech, Inc. 0.0065
MAIA Biotechnology, Inc. 0.00
Vericel Corp. 0.2556
Incyte Corp. 0.006
Regeneron Pharmaceuticals, Inc. 0.0854